Langenheim JF - Search Results

1

Activation of growth hormone receptors by growth hormone and growth hormone antagonist dimers: insights into receptor triggering.

Yang N, Langenheim JF, Wang X, Jiang J, Chen WY, Frank SJ. Yang N, et al. Among authors: langenheim jf. Mol Endocrinol. 2008 Apr;22(4):978-88. doi: 10.1210/me.2007-0424. Epub 2007 Dec 20. Mol Endocrinol. 2008. PMID: 18096690 Free PMC article.

2

Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists.

Langenheim JF, Tan D, Walker AM, Chen WY. Langenheim JF, et al. Mol Endocrinol. 2006 Mar;20(3):661-74. doi: 10.1210/me.2005-0360. Epub 2005 Nov 3. Mol Endocrinol. 2006. PMID: 16269515 Free PMC article.

3

Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex.

Xu J, Zhang Y, Berry PA, Jiang J, Lobie PE, Langenheim JF, Chen WY, Frank SJ. Xu J, et al. Among authors: langenheim jf. Mol Endocrinol. 2011 Apr;25(4):597-610. doi: 10.1210/me.2010-0255. Epub 2011 Feb 10. Mol Endocrinol. 2011. PMID: 21310852 Free PMC article.

4

The role of prolactin receptor in GH signaling in breast cancer cells.

Xu J, Sun D, Jiang J, Deng L, Zhang Y, Yu H, Bahl D, Langenheim JF, Chen WY, Fuchs SY, Frank SJ. Xu J, et al. Among authors: langenheim jf. Mol Endocrinol. 2013 Feb;27(2):266-79. doi: 10.1210/me.2012-1297. Epub 2012 Nov 28. Mol Endocrinol. 2013. PMID: 23192981 Free PMC article.

5

Dynamic analysis of GH receptor conformational changes by split luciferase complementation.

Liu Y, Berry PA, Zhang Y, Jiang J, Lobie PE, Paulmurugan R, Langenheim JF, Chen WY, Zinn KR, Frank SJ. Liu Y, et al. Among authors: langenheim jf. Mol Endocrinol. 2014 Nov;28(11):1807-19. doi: 10.1210/me.2014-1153. Epub 2014 Sep 4. Mol Endocrinol. 2014. PMID: 25188449 Free PMC article.

6

GHR/PRLR Heteromultimer Is Composed of GHR Homodimers and PRLR Homodimers.

Liu Y, Zhang Y, Jiang J, Lobie PE, Paulmurugan R, Langenheim JF, Chen WY, Zinn KR, Frank SJ. Liu Y, et al. Among authors: langenheim jf. Mol Endocrinol. 2016 May;30(5):504-17. doi: 10.1210/me.2015-1319. Epub 2016 Mar 22. Mol Endocrinol. 2016. PMID: 27003442 Free PMC article.

7

Development of a novel ligand that activates JAK2/STAT5 signaling through a heterodimer of prolactin receptor and growth hormone receptor.

Langenheim JF, Chen WY. Langenheim JF, et al. J Recept Signal Transduct Res. 2009;29(2):107-12. doi: 10.1080/10799890902845252. J Recept Signal Transduct Res. 2009. PMID: 19519175

8

Improving the pharmacokinetics/pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide.

Langenheim JF, Chen WY. Langenheim JF, et al. J Endocrinol. 2009 Dec;203(3):375-87. doi: 10.1677/JOE-09-0211. Epub 2009 Sep 21. J Endocrinol. 2009. PMID: 19770179

9

Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A.

Langenheim JF, Chen WY. Langenheim JF, et al. Breast Cancer Res Treat. 2005 Apr;90(3):281-93. doi: 10.1007/s10549-004-4816-9. Breast Cancer Res Treat. 2005. PMID: 15830142 Free PMC article.

10

Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.

Scotti ML, Langenheim JF, Tomblyn S, Springs AE, Chen WY. Scotti ML, et al. Among authors: langenheim jf. Breast Cancer Res Treat. 2008 Sep;111(2):241-50. doi: 10.1007/s10549-007-9789-z. Epub 2007 Oct 23. Breast Cancer Res Treat. 2008. PMID: 17955362

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters